SANUWAVE Announces Selection to Exhibit in the New Product Showcase at SAWC in Charlotte, April 25-29, 2018

SANUWAVE Announces Selection to Exhibit in the New Product Showcase at SAWC in Charlotte, April 25-29, 2018

SUWANEE, GA, April 11, 2018 (GLOBE NEWSWIRE) — SANUWAVE Health, Inc. (SNWVis pleased to announce that the company’s flagship wound care device, the dermaPACE® System, has been selected to be included in the New Product Showcase at SAWC (Symposium on Advanced Wound Care) in Charlotte, NC on April 25 – 29, 2018. This will be SANUWAVE’s first opportunity to present the dermaPACE® System to the U.S. market since receiving US FDA clearance in December 2017, allowing the company to market the device in the US.  The company will also be exhibiting in Booth 108.

“This is a great opportunity for SANUWAVE to be featured at SAWC as one of the new medical devices for 2018 in Charlotte.  New products are the prime reason people attend SAWC and having our device showcased will only increase our exposure at the show and allow us to get the word out about the dermaPACE® System,” stated Kevin R. Richardson, CEO and Chairman of the Board.  The Company is using this occasion to formally introduce their lead wound care product, the dermaPACE® System.  SANUWAVE’s proprietary PACE® (Pulsed Acoustic Cellular Expression) technology, based upon the focused, electrohydraulic shockwave principle, has been proven in two US based clinical trials enrolling 336 subjects to be safe and effective in the treatment of Diabetic Foot Ulcers (DFU).  The dermaPACE® System is the only shockwave device cleared or approved by FDA for the treatment of DFU.  Within a few weeks of initial treatment, wounds treated with dermaPACE® reduce in area at superior rates compared to control subjects.  The dermaPACE® System exhibits superiority in wound area reduction within 12 weeks of initial treatment and exhibits superiority in wound closure within 20 weeks of initial treatment.  The use of the dermaPACE® System allows the clinician to more easily, and more cost-effectively, manage wounds.   More importantly, the patient’s quality of life improves significantly.

If you are interested in scheduling a meeting with the team, please contact Peter Stegagno via e-mail at; otherwise, please stop by Booth Number 108 in addition to the New Product Showcase area of the exhibit hall to meet us and allow us to present the dermaPACE System.

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. (SNWV) ( is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is US FDA cleared for the treatment of Diabetic Foot Ulcers.  The device is also CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

For additional information about the Company, visit

Leave a Reply

Close Menu